Literature DB >> 17127261

Roles of transglutaminases in cardiac and vascular diseases.

David C Sane1, Jimmy L Kontos, Charles S Greenberg.   

Abstract

All transglutaminases share the common enzymatic activity of transamidation, or the cross-linking of glutamine and lysine residues to form N epsilon (gamma-glutamyl) lysyl isopeptide bonds. The plasma proenzyme factor XIII is responsible for stabilizing the fibrin clot against physical and fibrinolytic disruption. Another member of the transglutaminase family, tissue transglutaminase or TG2 is abundantly expressed in cardiomyocytes, vascular cells and macrophages. The transglutaminases have a variety of functions independent of their transamidating activity. For example, TG2 binds and hydrolyzes GTP, thereby fostering signal transduction by several G protein coupled receptors. Accumulating evidence points to novel roles for factor XIII and TG2 in cardiovascular biology including: (a) modulating platelet activity, (b) regulating glucose control, (c) contributing to the development of hypertension, (d) influencing the progression of atherosclerosis, (e) regulating vascular permeability and angiogenesis (f) and contributing to myocardial signaling, contractile activity and ischemia/reperfusion injury. In this review, we summarize the cardiovascular biology of two members of the family of transglutaminases, Factor XIII and TG2.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17127261      PMCID: PMC2762549          DOI: 10.2741/2253

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  195 in total

1.  Coagulation factor XIII and cardiovascular disease in UK Asian patients undergoing coronary angiography.

Authors:  D Warner; M W Mansfield; P J Grant
Journal:  Thromb Haemost       Date:  2001-03       Impact factor: 5.249

2.  Alpha 1-adrenergic receptor coupling with Gh in the failing human heart.

Authors:  K C Hwang; C D Gray; W E Sweet; C S Moravec; M J Im
Journal:  Circulation       Date:  1996-08-15       Impact factor: 29.690

3.  Cytofluorometric identification of plasmin-sensitive factor XIIIa binding to platelets.

Authors:  J A Kreager; D V Devine; C S Greenberg
Journal:  Thromb Haemost       Date:  1988-08-30       Impact factor: 5.249

4.  Phospholipase C-delta1 and oxytocin receptor signalling: evidence of its role as an effector.

Authors:  E S Park; J H Won; K J Han; P G Suh; S H Ryu; H S Lee; H Y Yun; N S Kwon; K J Baek
Journal:  Biochem J       Date:  1998-04-01       Impact factor: 3.857

5.  Cell surface transglutaminase promotes RhoA activation via integrin clustering and suppression of the Src-p190RhoGAP signaling pathway.

Authors:  Anna Janiak; Evgeny A Zemskov; Alexey M Belkin
Journal:  Mol Biol Cell       Date:  2006-02-01       Impact factor: 4.138

6.  ATP-binding cassette transporter A1 (ABCA1) in macrophages: a dual function in inflammation and lipid metabolism?

Authors:  G Schmitz; W E Kaminski; M Porsch-Ozcürümez; J Klucken; E Orsó; M Bodzioch; C Büchler; W Drobnik
Journal:  Pathobiology       Date:  1999       Impact factor: 4.342

Review 7.  The role of plaque rupture and thrombosis in coronary artery disease.

Authors:  A G Zaman; G Helft; S G Worthley; J J Badimon
Journal:  Atherosclerosis       Date:  2000-04       Impact factor: 5.162

8.  Small artery remodeling depends on tissue-type transglutaminase.

Authors:  Erik N T P Bakker; Carsten L Buus; Jos A E Spaan; Jop Perree; Anuradha Ganga; Titia M Rolf; Oana Sorop; Linda H Bramsen; Michael J Mulvany; Ed Vanbavel
Journal:  Circ Res       Date:  2004-11-18       Impact factor: 17.367

9.  Reduction of coagulation factor XIII concentration in patients with myocardial infarction, cerebral infarction, and other thromboembolic disorders.

Authors:  N Alkjaersig; A P Fletcher; M Lewis; R Ittyerah
Journal:  Thromb Haemost       Date:  1977-12-15       Impact factor: 5.249

10.  Soluble glycoprotein VI dimer inhibits platelet adhesion and aggregation to the injured vessel wall in vivo.

Authors:  Steffen Massberg; Ildiko Konrad; Andreas Bültmann; Christian Schulz; Götz Münch; Mario Peluso; Michael Lorenz; Simon Schneider; Felicitas Besta; Iris Müller; Bin Hu; Harald Langer; Elisabeth Kremmer; Martina Rudelius; Ulrich Heinzmann; Martin Ungerer; Meinrad Gawaz
Journal:  FASEB J       Date:  2003-12-04       Impact factor: 5.191

View more
  29 in total

1.  Transglutaminase 2 in pulmonary and cardiac tissue remodeling in experimental pulmonary hypertension.

Authors:  Krishna C Penumatsa; Deniz Toksoz; Rod R Warburton; Mousa Kharnaf; Ioana R Preston; Navin K Kapur; Chaitan Khosla; Nicholas S Hill; Barry L Fanburg
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-08-03       Impact factor: 5.464

2.  Vena cava and aortic smooth muscle cells express transglutaminases 1 and 4 in addition to transglutaminase 2.

Authors:  Kyle B Johnson; Humphrey Petersen-Jones; Janice M Thompson; Kiyotaka Hitomi; Miho Itoh; Erik N T P Bakker; Gail V W Johnson; Gozde Colak; Stephanie W Watts
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-02-03       Impact factor: 4.733

3.  Reactivity of the N-terminal region of fibronectin protein to transglutaminase 2 and factor XIIIA.

Authors:  Brian R Hoffmann; Douglas S Annis; Deane F Mosher
Journal:  J Biol Chem       Date:  2011-07-11       Impact factor: 5.157

Review 4.  Transglutaminase 2-mediated serotonylation in pulmonary hypertension.

Authors:  K C Penumatsa; B L Fanburg
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-12-27       Impact factor: 5.464

Review 5.  Anti-type 2 transglutaminase antibodies as modulators of type 2 transglutaminase functions: a possible pathological role in celiac disease.

Authors:  Stefania Martucciello; Gaetana Paolella; Carla Esposito; Marilena Lepretti; Ivana Caputo
Journal:  Cell Mol Life Sci       Date:  2018-08-22       Impact factor: 9.261

6.  The vicious cycle between transglutaminase 2 and reactive oxygen species in hyperglycemic memory-induced endothelial dysfunction.

Authors:  Jee-Yeon Lee; Yeon-Ju Lee; Hye-Yoon Jeon; Eun-Taek Han; Won Sun Park; Seok-Ho Hong; Young-Myeong Kim; Kwon-Soo Ha
Journal:  FASEB J       Date:  2019-08-28       Impact factor: 5.191

Review 7.  Cellular functions of tissue transglutaminase.

Authors:  Maria V Nurminskaya; Alexey M Belkin
Journal:  Int Rev Cell Mol Biol       Date:  2012       Impact factor: 6.813

8.  Arterial vimentin is a transglutaminase substrate: a link between vasomotor activity and remodeling?

Authors:  Madhu Gupta; Charles S Greenberg; Delrae M Eckman; David C Sane
Journal:  J Vasc Res       Date:  2007-05-03       Impact factor: 1.934

9.  Developmental basis for filamin-A-associated myxomatous mitral valve disease.

Authors:  Kimberly Sauls; Annemarieke de Vlaming; Brett S Harris; Katherine Williams; Andy Wessels; Robert A Levine; Susan A Slaugenhaupt; Richard L Goodwin; Luigi Michele Pavone; Jean Merot; Jean-Jacques Schott; Thierry Le Tourneau; Thomas Dix; Sean Jesinkey; Yuanyi Feng; Christopher Walsh; Bin Zhou; Scott Baldwin; Roger R Markwald; Russell A Norris
Journal:  Cardiovasc Res       Date:  2012-07-25       Impact factor: 10.787

10.  The interaction of angiocidin with tissue transglutaminase.

Authors:  Darryl Z L'Heureux; Vicki L Rothman; George P Tuszynski
Journal:  Exp Mol Pathol       Date:  2009-11-18       Impact factor: 3.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.